Angelini Pharma Secures Global Rights To Brain Health Treatment With Cureverse Deal

Angelini Pharma, a subsidiary of the privately-held Angelini Industries, has partnered with Cureverse Inc., a research and development firm, through an exclusive global option agreement to advance and commercialize Cureverse's groundbreaking brain health asset, CV-01. As part of the agreement, Angelini Pharma will take charge of all development activities for CV-01. 

After an initial option period, Angelini will have the exclusive rights to globally develop and commercialize the compound, with the exception of markets in the Republic of Korea, China, Hong Kong, Macau, and Taiwan. CV-01, a promising investigational compound, works by activating protective mechanisms controlled by the nuclear factor erythroid 2-related factor 2 (Nrf2). 

This innovative approach could make CV-01 a potential disease-modifying treatment for various brain health conditions, including epilepsy. Currently undergoing Phase 1 clinical trials in South Korea, CV-01 is also being explored as a treatment for Alzheimer's disease. Cureverse will receive an initial payment upfront and stands to earn up to approximately $360 million through a series of pre-determined development and commercial milestones. In addition, they will be eligible for tiered royalties based on net sales once the product is approved and brought to market.

Jacopo Andreose, Chief Executive Officer of Angelini Pharma, said in a statement, “Our strategic collaboration with Cureverse further strengthens Angelini Pharma’s position as an emerging leader in brain health. Neurological conditions such as epilepsy are among leading causes of disease burden worldwide. While significant progress has been achieved in the past 15 years, many people living with epilepsy are still unable to reach seizure control despite combination treatment of several anti-seizure medications.[iii] Through the development of CV-01 and potentially other compounds, we aim to provide much-needed solutions for people living with brain health conditions across the world.”

Sung Jin Cho, Chief Executive Officer at Cureverse Inc., mentioned, “Our research has unveiled the remarkable potential of CV-01 to transform the landscape of brain health, from epilepsy to Alzheimer’s and Parkinson’s Disease. We are truly delighted to be partnering with Angelini Pharma on this journey. Their deep therapeutic expertise and commitment to brain health perfectly align with our vision. Together, we are not just developing a treatment—we are paving the way for a future where patients with neurological conditions have access to truly life-changing therapies.”